About

About

About

About

About

Established in 2022, Pictura Bio is engineering its way to instantaneous diagnostics through cutting edge technology and machine learning.

Established in 2022, Pictura Bio is engineering its way to instantaneous diagnostics through cutting edge technology and machine learning.

Established in 2022, Pictura Bio is engineering its way to instantaneous diagnostics through cutting edge technology and machine learning.

Established in 2022, Pictura Bio is engineering its way to instantaneous diagnostics through cutting edge technology and machine learning.

Established in 2022, Pictura Bio is engineering its way to instantaneous diagnostics through cutting edge technology and machine learning.

A spin out from the University of Oxford, the Pictura Bio team combines biology and optical engineering with machine learning to bring the efficiency of digital technology to diagnostic testing. Having already delivered a prototype to the Defence and Security Accelerator (part of the UK Ministry of Defence), established partnerships with the Emergency Department at NHS Portsmouth and NHS and private GPs, the benchtop VISTA device and proprietary PIC-ID technology is in reach.

A spin out from the University of Oxford, the Pictura Bio team combines biology and optical engineering with machine learning to bring the efficiency of digital technology to diagnostic testing. Having already delivered a prototype to the Defence and Security Accelerator (part of the UK Ministry of Defence), established partnerships with the Emergency Department at NHS Portsmouth and NHS and private GPs, the benchtop VISTA device and proprietary PIC-ID technology is in reach.

A spin out from the University of Oxford, the Pictura Bio team combines biology and optical engineering with machine learning to bring the efficiency of digital technology to diagnostic testing. Having already delivered a prototype to the Defence and Security Accelerator (part of the UK Ministry of Defence), established partnerships with the Emergency Department at NHS Portsmouth and NHS and private GPs, the benchtop VISTA device and proprietary PIC-ID technology is in reach.

A spin out from the University of Oxford, the Pictura Bio team combines biology and optical engineering with machine learning to bring the efficiency of digital technology to diagnostic testing. Having already delivered a prototype to the Defence and Security Accelerator (part of the UK Ministry of Defence), established partnerships with the Emergency Department at NHS Portsmouth and NHS and private GPs, the benchtop VISTA device and proprietary PIC-ID technology is in reach.

A spin out from the University of Oxford, the Pictura Bio team combines biology and optical engineering with machine learning to bring the efficiency of digital technology to diagnostic testing. Having already delivered a prototype to the Defence and Security Accelerator (part of the UK Ministry of Defence), established partnerships with the Emergency Department at NHS Portsmouth and NHS and private GPs, the benchtop VISTA device and proprietary PIC-ID technology is in reach.

Leadership Team

Leadership Team

Leadership Team

Leadership Team

Leadership Team

Alex Batchelor - CEO of Pictura BIo

CEO

Alex Batchelor

View bio

Alex Batchelor - CEO of Pictura BIo

CEO

Alex Batchelor

View bio

Alex Batchelor - CEO of Pictura BIo

CEO

Alex Batchelor

View bio

Alex Batchelor - CEO of Pictura BIo

CEO

Alex Batchelor

View bio

Alex Batchelor - CEO of Pictura BIo

CEO

Alex Batchelor

View bio

Nicolas Shiaelis - Scientific Co-Founder of Pictura BIo

Scientific Co-Founder

Nicolas Shiaelis

View bio

Nicolas Shiaelis - Scientific Co-Founder of Pictura BIo

Scientific Co-Founder

Nicolas Shiaelis

View bio

Nicolas Shiaelis - Scientific Co-Founder of Pictura BIo

Scientific Co-Founder

Nicolas Shiaelis

View bio

Nicolas Shiaelis - Scientific Co-Founder of Pictura BIo

Scientific Co-Founder

Nicolas Shiaelis

View bio

Nicolas Shiaelis - Scientific Co-Founder of Pictura BIo

Scientific Co-Founder

Nicolas Shiaelis

View bio

Dr. Nicole Robb - Scientific Co-Founder of Pictura BIo

Scientific Co-Founder

Dr. Nicole Robb

View bio

Dr. Nicole Robb - Scientific Co-Founder of Pictura BIo

Scientific Co-Founder

Dr. Nicole Robb

View bio

Dr. Nicole Robb - Scientific Co-Founder of Pictura BIo

Scientific Co-Founder

Dr. Nicole Robb

View bio

Dr. Nicole Robb - Scientific Co-Founder of Pictura BIo

Scientific Co-Founder

Dr. Nicole Robb

View bio

Dr. Nicole Robb - Scientific Co-Founder of Pictura BIo

Scientific Co-Founder

Dr. Nicole Robb

View bio

Tom Amies - CFO of Pictura BIo

CFO

Tom Amies

View bio

Tom Amies - CFO of Pictura BIo

CFO

Tom Amies

View bio

Tom Amies - CFO of Pictura BIo

CFO

Tom Amies

View bio

Tom Amies - CFO of Pictura BIo

CFO

Tom Amies

View bio

Tom Amies - CFO of Pictura BIo

CFO

Tom Amies

View bio

Chris Stampfl - CBO of Pictura BIo

Chief Business Officer

Chris Stampfl

View bio

Chris Stampfl - CBO of Pictura BIo

Chief Business Officer

Chris Stampfl

View bio

Chris Stampfl - CBO of Pictura BIo

Chief Business Officer

Chris Stampfl

View bio

Chris Stampfl - CBO of Pictura BIo

Chief Business Officer

Chris Stampfl

View bio

Chris Stampfl - CBO of Pictura BIo

Chief Business Officer

Chris Stampfl

View bio

Advisors

Advisors

Advisors

Advisors

Advisors

Rachel Gauntlett

Rachel Gauntlett

View bio

Rachel Gauntlett

Rachel Gauntlett

View bio

Rachel Gauntlett

Rachel Gauntlett

View bio

Rachel Gauntlett

Rachel Gauntlett

View bio

Rachel Gauntlett

Rachel Gauntlett

View bio

Dr. Rishi Chopra - Advisor to Pictura Bio

Dr. Rishi Chopra

View bio

Dr. Rishi Chopra - Advisor to Pictura Bio

Dr. Rishi Chopra

View bio

Dr. Rishi Chopra - Advisor to Pictura Bio

Dr. Rishi Chopra

View bio

Dr. Rishi Chopra - Advisor to Pictura Bio

Dr. Rishi Chopra

View bio

Dr. Rishi Chopra - Advisor to Pictura Bio

Dr. Rishi Chopra

View bio

Dr. Richard Dawood - Advisor to Pictura Bio

Dr Richard Dawood

View bio

Dr. Richard Dawood - Advisor to Pictura Bio

Dr Richard Dawood

View bio

Dr. Richard Dawood - Advisor to Pictura Bio

Dr Richard Dawood

View bio

Dr. Richard Dawood - Advisor to Pictura Bio

Dr Richard Dawood

View bio

Dr. Richard Dawood - Advisor to Pictura Bio

Dr Richard Dawood

View bio

Professor Miles Caroll - Advisor to Pictura Bio

Professor Miles Caroll

View bio

Professor Miles Caroll - Advisor to Pictura Bio

Professor Miles Caroll

View bio

Professor Miles Caroll - Advisor to Pictura Bio

Professor Miles Caroll

View bio

Professor Miles Caroll - Advisor to Pictura Bio

Professor Miles Caroll

View bio

Professor Miles Caroll - Advisor to Pictura Bio

Professor Miles Caroll

View bio

Iain Miller

Dr. Iain Miller

View bio

Iain Miller

Dr. Iain Miller

View bio

Iain Miller

Dr. Iain Miller

View bio

Iain Miller

Dr. Iain Miller

View bio

Iain Miller

Dr. Iain Miller

View bio

Our Investors

Our Investors

Our Investors

Our Investors

Our Investors

Pictura Bio holds IP rights over the two key components of the PIC-ID technology – the universal label and the deep learning algorithm – and has secured £2.6 million in pre-seed funding from IQ Capital Partners, Ahren Innovation Capital and ScienceCreates Ventures.

Pictura Bio holds IP rights over the two key components of the PIC-ID technology – the universal label and the deep learning algorithm – and has secured £2.6 million in pre-seed funding from IQ Capital Partners, Ahren Innovation Capital and ScienceCreates Ventures.

Pictura Bio holds IP rights over the two key components of the PIC-ID technology – the universal label and the deep learning algorithm – and has secured £2.6 million in pre-seed funding from IQ Capital Partners, Ahren Innovation Capital and ScienceCreates Ventures.

Pictura Bio holds IP rights over the two key components of the PIC-ID technology – the universal label and the deep learning algorithm – and has secured £2.6 million in pre-seed funding from IQ Capital Partners, Ahren Innovation Capital and ScienceCreates Ventures.

Pictura Bio holds IP rights over the two key components of the PIC-ID technology – the universal label and the deep learning algorithm – and has secured £2.6 million in pre-seed funding from IQ Capital Partners, Ahren Innovation Capital and ScienceCreates Ventures.

While there is nothing similar to PIC-ID on the market, other companies in the computer vision and machine learning medical space – such as digital pathology platforms that can analyse images of tumour tissue or AI-assisted analysis of X-ray scans – demonstrate a clear and viable route to regulatory approval and reimbursement for Pictura Bio’s technology.

Given the global scale of infectious disease and the ever-present threat of emerging diseases, there’s a huge potential market to be tapped.

The global infectious disease diagnostics market was valued at $45.24 billion in 2024, and is expected to reach $53.68 billion by 2029. Add in future applications in other diseases, and the opportunities are vast.

With no direct competition in the image-based infectious disease diagnostics field, Pictura Bio is uniquely placed as the global front-runner in this space.

While there is nothing similar to PIC-ID on the market, other companies in the computer vision and machine learning medical space – such as digital pathology platforms that can analyse images of tumour tissue or AI-assisted analysis of X-ray scans – demonstrate a clear and viable route to regulatory approval and reimbursement for Pictura Bio’s technology.

Given the global scale of infectious disease and the ever-present threat of emerging diseases, there’s a huge potential market to be tapped.

The global infectious disease diagnostics market was valued at $45.24 billion in 2024, and is expected to reach $53.68 billion by 2029. Add in future applications in other diseases, and the opportunities are vast.

With no direct competition in the image-based infectious disease diagnostics field, Pictura Bio is uniquely placed as the global front-runner in this space.

While there is nothing similar to PIC-ID on the market, other companies in the computer vision and machine learning medical space – such as digital pathology platforms that can analyse images of tumour tissue or AI-assisted analysis of X-ray scans – demonstrate a clear and viable route to regulatory approval and reimbursement for Pictura Bio’s technology.

Given the global scale of infectious disease and the ever-present threat of emerging diseases, there’s a huge potential market to be tapped.

The global infectious disease diagnostics market was valued at $45.24 billion in 2024, and is expected to reach $53.68 billion by 2029. Add in future applications in other diseases, and the opportunities are vast.

With no direct competition in the image-based infectious disease diagnostics field, Pictura Bio is uniquely placed as the global front-runner in this space.

While there is nothing similar to PIC-ID on the market, other companies in the computer vision and machine learning medical space – such as digital pathology platforms that can analyse images of tumour tissue or AI-assisted analysis of X-ray scans – demonstrate a clear and viable route to regulatory approval and reimbursement for Pictura Bio’s technology.

Given the global scale of infectious disease and the ever-present threat of emerging diseases, there’s a huge potential market to be tapped.

The global infectious disease diagnostics market was valued at $45.24 billion in 2024, and is expected to reach $53.68 billion by 2029. Add in future applications in other diseases, and the opportunities are vast.

With no direct competition in the image-based infectious disease diagnostics field, Pictura Bio is uniquely placed as the global front-runner in this space.

While there is nothing similar to PIC-ID on the market, other companies in the computer vision and machine learning medical space – such as digital pathology platforms that can analyse images of tumour tissue or AI-assisted analysis of X-ray scans – demonstrate a clear and viable route to regulatory approval and reimbursement for Pictura Bio’s technology.

Given the global scale of infectious disease and the ever-present threat of emerging diseases, there’s a huge potential market to be tapped.

The global infectious disease diagnostics market was valued at $45.24 billion in 2024, and is expected to reach $53.68 billion by 2029. Add in future applications in other diseases, and the opportunities are vast.

With no direct competition in the image-based infectious disease diagnostics field, Pictura Bio is uniquely placed as the global front-runner in this space.

Request investor pack

Request investor pack

Request investor pack

Request investor pack

Request investor pack

Traction

Started Jan 2023 → ongoing: Clinical Trial

Novel Technologies for Respiratory Virus Identification (ResVir) [NCT05661032]

Our first clinical study is being conducted in partnership with the Queen Alexandra Hospital in Portsmouth, England. This is our first large-scale sample collection initiative where we aim to generate a large respiratory pathogen dataset on which we are continuously training PIC-ID Identify.
Read more

Aug 2023: Innovate UK SMART Grant

Our project culminated in the completion of our first prototype instrument in late 2022 providing proof of principle for an end-to-end automated workflow from cartridge insertion to test result.

November 2023: US Subsidiary Established

Key territory for Pictura, we opened a subsidiary office in the US to ensure market access as our technology develops.

February 2024: Defence and Security Accelerator Contract Completed

We recently completed a contract with the UK Defense and Security Accelerator (DASA) successfully building a ruggedized automated system and detected bacteria for the first time, with all engineering components contained within a portable case.

June 2025: Innovate UK Investor Partnership Project

Our latest Innovate UK funded project will allow us to continue development of our device to an alpha prototype. This includes size reduction of the VISTA Reader to a commercially acceptable size, whilst simultaneously improving PIC-ID Capture and training PIC-ID Identify. We anticipate the project will be completed by mid 2025.

June 2025 - VISTA Alpha

Our first near market ready system will be ready for broader testing with key partners and small scale manufacturing

July 2026 - VISTA Beta

Our system will be ready for clinical trials, broader adoption, as well as scaled-up manufacturing.